A Study of Cytisinicline for Vaping Cessation in Adult Smokers
Status:
Not yet recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This placebo-controlled Phase 2 study is being conducted at sites within the United States to
evaluate the safety profile of 3 mg cytisinicline administered TID for 12 weeks.